Get the Stockscreener App
25.64
1.16%
-0.30
After Hours:
25.30
-0.34
-1.33%
Immunovant Inc stock is traded at $25.64, with a volume of 1.17M.
It is down -1.16% in the last 24 hours and down -0.66% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$25.94
Open:
$26.01
24h Volume:
1.17M
Relative Volume:
0.72
Market Cap:
$5.22B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-9.7863
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
+6.57%
1M Performance:
-0.66%
6M Performance:
+68.57%
1Y Performance:
+33.40%
1-Day Range:
$25.09
$26.41
1-Week Range:
$24.85
$27.92
52-Week Range:
$12.72
$27.92
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-410-3120
Address
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
25.64 | 5.28B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Immunovant (NASDAQ:IMVT) Given Buy Rating at HC Wainwright - MarketBeat
Immunovant stock hits all-time high at 27.87 USD By Investing.com - Investing.com Canada
Immunovant Rides Brepocitinib Momentum Into 2026 - TipRanks
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Finviz
Immunovant (NASDAQ:IMVT) Hits New 12-Month High After Earnings Beat - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV) - The Globe and Mail
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy - MSN
A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway - Yahoo Finance
Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript - Insider Monkey
Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones - AlphaStreet News
Decoding Immunovant Inc (IMVT): A Strategic SWOT Insight - GuruFocus
Does Immunovant’s (IMVT) Narrower Quarterly Per‑Share Loss Reframe Its Long‑Term Risk‑Reward Equation? - simplywall.st
Earnings call transcript: Immunovant beats Q3 2026 EPS expectations, stock surges - Investing.com Nigeria
Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected - MSN
IMVT: Brepocitinib delivered strong phase 2 efficacy in cutaneous sarcoidosis, advancing to phase 3 - TradingView
Immunovant (NASDAQ:IMVT) Shares Gap Up Following Strong Earnings - MarketBeat
Immunovant Q3 Earnings Call Highlights - MarketBeat
IMVT: Brepocitinib phase 2 data in cutaneous sarcoidosis showed 100% high-dose response and strong safety - TradingView
Immunovant Fiscal Q3 Loss Narrows; Shares Up Pre-Bell - marketscreener.com
Immunovant shares jump 7% as Q3 loss narrows, beats estimates By Investing.com - Investing.com Nigeria
IMMUNOVANT ($IMVT) Releases Q3 2026 Earnings - Quiver Quantitative
Earnings Flash (IMVT) Immunovant Posts Fiscal Q3 Loss $0.61 a Share, vs. FactSet Est of $0.69 Loss - marketscreener.com
Immunovant's Q3 2025 Financial Results and Corporate Updates - TradingView
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 - The Manila Times
Immunovant (Nasdaq: IMVT) posts Q3 loss but boosts cash with $550M raise - Stock Titan
Immunovant earnings up next as Graves’ disease optimism builds By Investing.com - Investing.com Nigeria
Immunovant earnings up next as Graves’ disease optimism builds - Investing.com
Immunovant’s Upcoming Report to Spotlight Clinical Pipeline Progress - AD HOC NEWS
Immunovant, Inc. (IMVT) Stock Analysis: A Biotech Gem With 54.57% Potential Upside - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (IMVT) Edition - Stock Traders Daily
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know - Finviz
Immunovant (IMVT) Expected to Post Quarterly Earnings on Friday - MarketBeat
Breakout Zone: What are analysts price targets for Immunovant Inc2025 Volume Leaders & Weekly Top Stock Performers List - baoquankhu1.vn
Immunovant, Inc. (IMVT) Stock Analysis: Exploring a 51.55% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Investors Purchase High Volume of Call Options on Immunovant (NASDAQ:IMVT) - MarketBeat
Published on: 2026-01-26 14:49:08 - baoquankhu1.vn
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - The Manila Times
Immunovant (NASDAQ:IMVT) CTO Jay Stout Sells 1,977 Shares - MarketBeat
(IMVT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immunovant, Inc. (IMVT) Stock Analysis: A Biotech Marvel With 53% Potential Upside - DirectorsTalk Interviews
SG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat
Merger Talk: What are Immunovant Incs earnings expectationsTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Assessing Immunovant (IMVT) Valuation After Strong 90 Day Share Price Momentum - Yahoo Finance
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% - Finviz
Immunovant (NASDAQ:IMVT) Stock Price Down 5.7%Should You Sell? - MarketBeat
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stout Jay S | Chief Technology Officer |
Jan 21 '26 |
Sale |
26.03 |
1,977 |
51,461 |
197,634 |
| Stout Jay S | Chief Technology Officer |
Jan 07 '26 |
Sale |
26.53 |
1,203 |
31,914 |
199,611 |
| Van Tuyl Christopher | Chief Legal Officer |
Dec 18 '25 |
Sale |
26.91 |
10,813 |
290,943 |
149,930 |
| Roivant Sciences Ltd. | Director |
Dec 12 '25 |
Buy |
21.00 |
16,666,666 |
349,999,986 |
113,317,007 |
| Fromkin Andrew J. | Director |
Dec 01 '25 |
Sale |
23.25 |
22,249 |
517,189 |
85,852 |
| Hughes Douglas J. | Director |
Dec 01 '25 |
Sale |
23.24 |
15,000 |
348,665 |
120,773 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):